Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Welcome to the Viking Therapeutics Fourth Quarter and Full ... Viking closed a successful public offering of common stock, raising more than $630 million in gross proceeds, providing the resources ...

Research analysts predict that Viking Therapeutics will post -0.97 EPS ... owns 1,004,033 shares of the biotechnology company’s stock worth $63,565,000 after acquiring an additional 994,801 ...

Viking Therapeutics' promising pipeline ... was 2024, with its stock skyrocketing 584%. And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...